Back

Prophylactic ranolazine and trimetazidine attenuate right ventricular dysfunction and improve exercise capacity in experimental pulmonary hypertension

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension: pre-clinical Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speakers

Photo
Doctor Suha Asal

Ministry of Health Corlu State Hospital, Istanbul (Turkiye)

Photo
Doctor Ahmet Oz

Istanbul Education and Research Hospital, Istanbul (Turkiye)

5 More presentations in this session

Presentation thumbnail
Insulin resistance genetic susceptibility drives pulmonary arterial hypertension through monocyte metabolic reprogramming and immune dysregulation
Mr S. Hou (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Interleukin-22–STAT3 Signaling Preserves Structural Integrity in the Pressure-Overloaded Right Ventricle
Doctor K. Shibao (Kurume, JP)
Abstract Slides Video
Presentation thumbnail
Empagliflozin attenuates pulmonary vascular hemodynamic progression and improves right ventricular adaptation in overcirculation-induced pulmonary hypertension
Doctor A. Garcia-Alvarez (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Myo-inositol trispyrophosphate improves oxygen delivery and right ventricular function in rat pressure overload model
Doctor M. Maczewski (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Targeting the PSMB9–NGAL/MMP9 Axis: a novel neutrophil-driven mechanism and precision target for vascular remodeling in PAH
Associate Professor X. He (Guangzhou, CN)
Abstract Slides

Access the full session

Session thumbnail
Pulmonary hypertension: pre-clinical

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Investigating the effect of colchicine treatment on pulmonary arterial hypertension in a rat model
22 May 2023
thumbnail
Congress Presentation
Comparative effects of ranolazine and trimetazidine on cardiac structure and exercise capacity in a healthy rat model: a new doping agent?
31 August 2024
thumbnail
Congress Presentation
The exercise tolerance dependence on epicardial fat thickness, right ventricular hypertrophy and right ventricular global function in patients with metabolic syndrome
27 August 2022
thumbnail
Congress Presentation
Right ventricle function improvement with sacubitril/valsartan therapy
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources